Firmonertinib misses primary endpoint in Phase 3 FURVENT trial in EGFR exon 20 NSCLC
ArriVent BioPharma, Inc. announced that the FURVENT (NCT05607550) Phase 3 trial evaluating firmonertinib monotherapy in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer… read more.
